61 – 70 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation
- Contribution to journal › Article
-
Mark
Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker
- Contribution to journal › Article
- 2016
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
- Contribution to journal › Article
- 2015
-
Mark
Intrinsic subtypes and prognostic implications in epithelial ovarian cancer
- Thesis › Doctoral thesis (compilation)
-
Mark
Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
- Contribution to journal › Article
-
Mark
Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
- Contribution to journal › Article
-
Mark
Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort
- Contribution to journal › Article
- 2014
-
Mark
Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer
- Contribution to journal › Article
- 2013
-
Mark
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer
- Contribution to journal › Article
-
Mark
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.
- Contribution to journal › Article
